share_log

Aethlon Medical Announces Pricing of $4.7 Million Public Offering

Aethlon Medical Announces Pricing of $4.7 Million Public Offering

Aethlon Medical宣佈470萬美元公開募股的定價
PR Newswire ·  05/15 21:15

SAN DIEGO, May 15, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 8,100,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class A warrants to purchase up to 8,100,000 shares of common stock, and Class B warrants to purchase up to 8,100,000 shares of common stock, at a combined public offering price of $0.58 per share (or pre-funded warrant) and accompanying warrants. The warrants will have an exercise price of $0.58 per share, subject to an adjustment, will be exercisable immediately upon issuance and, in the case of Class A warrants, will expire on the fifth anniversary of the original issuance date, and in the case of Class B warrants, will expire on the one year anniversary of the original issuance date. The closing of the offering is expected to occur on or about May 17, 2024, subject to the satisfaction of customary closing conditions.

聖地亞哥,2024年5月15日 /PRNewswire/ — 專注於開發治療癌症和危及生命的傳染病產品的藥物治療公司艾思龍醫療公司(納斯達克股票代碼:AEMD)今天宣佈,公開發行總額爲8,100,000股普通股(或代之以預先籌資的認股權證)的定價,購買最多8,100,000股普通股的A類認股權證,以及購買最多8,100,000股普通股的B類認股權證,合併公開發行價格爲每股0.58美元(或預先注資的認股權證),以及隨附的認股權證。認股權證的行使價爲每股0.58美元,但需進行調整,可在發行後立即行使,對於A類認股權證,將在原始發行日期的五週年之日到期;對於B類認股權證,將在原始發行日期的一週年之日到期。此次發行預計將於2024年5月17日左右結束,但須滿足慣例成交條件。

Maxim Group LLC is acting as the exclusive placement agent for the offering.

Maxim Group LLC是此次發行的獨家配售代理。

The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $4.7 million. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include clinical trial expenses, research and development expenses, capital expenditures and working capital.

在扣除配售代理費用和其他發行費用之前,此次發行的總收益預計約爲470萬美元。公司打算將本次發行的淨收益用於一般公司用途,其中可能包括臨床試驗費用、研發費用、資本支出和營運資金。

The securities described above are being offered pursuant to a registration statement on Form S-1, as amended (File No. 333-278188), which was declared effective by the Securities and Exchange Commission (the "SEC") on May 15, 2024. The offering is being made only by means of a prospectus which forms a part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC's website at www.sec.gov and may also be obtained by contacting Maxim Group LLC at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (212) 895-3745 or by email at [email protected].

上述證券是根據經修訂的S-1表格(文件編號333-278188)的註冊聲明發行的,該聲明於2024年5月15日由美國證券交易委員會(“SEC”)宣佈生效。此次發行僅通過招股說明書進行,招股說明書是有效註冊聲明的一部分。與本次發行有關的初步招股說明書已提交給美國證券交易委員會。最終招股說明書的電子副本(如果有)可在美國證券交易委員會的網站www.sec.gov上獲得,也可以聯繫位於紐約公園大道300號16樓的Maxim集團有限責任公司,收件人:招股說明書部,或致電(212)895-3745或發送電子郵件至 [email protected] 獲取。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

本新聞稿不構成出售要約或招攬購買本文所述任何證券的要約,也不得在根據任何此類州或其他司法管轄區的證券法進行註冊或資格認證之前,在任何州或其他司法管轄區出售這些證券是非法的。

About Aethlon and the Hemopurifier

關於 Aethlon 和 Hemopurifier

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration ("FDA") designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Aethlon Medical是一家醫療治療公司,專注於開發血液淨化器,這是一種臨床階段的免疫治療設備,旨在對抗癌症和危及生命的病毒感染,並用於器官移植。在人體研究中,血液淨化器已證明可以去除危及生命的病毒;在臨床前研究中,血液淨化器已證明利用其專有的凝集素基技術從生物液體中去除有害的外泌體。這種作用在癌症(外泌體可能促進免疫抑制和轉移)以及危及生命的傳染病中具有潛在的應用。Hemopurifier 是美國食品藥品監督管理局(“FDA”)指定的突破性設備,適用於治療對標準護理療法無反應或不耐受的晚期或轉移性癌症患者,以及外泌體已被證明參與疾病發展或嚴重程度的癌症類型的患者。Hemopurifier還擁有美國食品藥品管理局突破性設備稱號和一份公開的研究設備豁免申請,該申請涉及治療經批准的療法無法解決的危及生命的病毒。

Forward-Looking Statements

前瞻性陳述

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties, including statements regarding the size of the offering, the anticipated timing of and the Company's ability to close the offering, and the use of the net proceeds from the offering. Words such as "anticipate," "expect," "intend," "may," "will," "potentially" or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon the Company's current expectations, estimates and projections about the Company's business, which are subject to a number of known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with market conditions and risks related to the Company's business. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in the Company's other filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

本新聞稿包含經修訂的1933年《證券法》第27A條和經修訂的1934年《證券交易法》第21E條所指的前瞻性陳述,這些陳述涉及風險和不確定性,包括有關發行規模、預期時間和公司完成發行的能力,以及發行淨收益的用途的陳述。諸如 “預期”、“期望”、“打算”、“可能”、“將”、“可能”、“可能”、“可能地” 或類似表述之類的詞語旨在識別前瞻性陳述,儘管並非所有前瞻性陳述都一定包含這些識別詞。這些前瞻性陳述基於公司當前對公司業務的預期、估計和預測,這些預期、估計和預測存在許多已知和未知的風險,涉及可能永遠無法實現或可能被證明不正確的假設。由於各種風險和不確定性,包括但不限於與市場狀況相關的風險和與公司業務相關的風險,實際業績和事件發生的時間可能與此類前瞻性陳述中的預期存在重大差異。上述風險和不確定性清單是說明性的,但並非詳盡無遺。可能導致業績與前瞻性陳述中的預期存在重大差異的其他因素可以在公司截至2023年3月31日的10-K表年度報告以及公司向美國證券交易委員會提交的其他文件(包括其10-Q表季度報告)中的 “風險因素” 標題下找到。本新聞稿中包含的所有前瞻性陳述僅代表其發佈之日。除非法律要求,否則公司不打算也不承擔任何義務更新這些信息以反映未來的事件或情況。

Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
[email protected]

公司聯繫人:
吉姆·弗雷克斯
臨時首席執行官兼首席財務官
Aethlon Medical, Inc.
[電子郵件保護]

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
[email protected]
917-513-5303

投資者聯繫人:
蘇珊·努南
S.A. Noonan 通信有限責任公司
[電子郵件保護]
917-513-5303

SOURCE Aethlon Medical, Inc.

來源 Aethlon Medical, Inc.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論